• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Lantheus' blood pool agent lights up your life

Publication
Article
Diagnostic ImagingDiagnostic Imaging Vol 32 No 6
Volume 32
Issue 6

Ablavar, the only commercially available blood pool MR contrast agent, lights up vasculature in this steady-state MR angiogram.

Ablavar, the only commercially available blood pool MR contrast agent, lights up vasculature in this steady-state MR angiogram. The agent entered the U.S. market early this year under the auspices of Lantheus Medical, a provider of ultrasound and nuclear medicine imaging agents. A different company, Epix Pharmaceuticals, had developed the agent, however, under the name Vasovist, and won FDA approval in December 2008 after a long struggle with American regulators.

Epix sold the U.S., Canadian, and Australian rights to market the agent to Lantheus in April 2008 for $28 million in a futile attempt to stay afloat after the company had switched its focus to the development of therapeutic drugs. Epix declared bankruptcy a year ago.

Its unique injectable MR angiography agent is approved by the FDA to evaluate aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease, producing high-resolution images with a single dose. Ablavar's albumin-binding properties allow the agent to persist in circulation for an extended time, illustrating vascular anomalies in both dynamic (first-pass) and steady-state imaging.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.